CN116648256A - 稳定化的tcr构建体及使用方法 - Google Patents

稳定化的tcr构建体及使用方法 Download PDF

Info

Publication number
CN116648256A
CN116648256A CN202180086149.4A CN202180086149A CN116648256A CN 116648256 A CN116648256 A CN 116648256A CN 202180086149 A CN202180086149 A CN 202180086149A CN 116648256 A CN116648256 A CN 116648256A
Authority
CN
China
Prior art keywords
tcr
trac
amino acid
trbc
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180086149.4A
Other languages
English (en)
Chinese (zh)
Inventor
E·埃斯科巴-卡布瑞拉
L·弗赖伯格
D·T·巴顿
L·G·普雷斯塔
P·法伯
C·M·史蒂文斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeast Biopharmaceutical Co ltd
Original Assignee
Yeast Biopharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeast Biopharmaceutical Co ltd filed Critical Yeast Biopharmaceutical Co ltd
Publication of CN116648256A publication Critical patent/CN116648256A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180086149.4A 2020-12-21 2021-12-21 稳定化的tcr构建体及使用方法 Pending CN116648256A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063128601P 2020-12-21 2020-12-21
US63/128,601 2020-12-21
PCT/CA2021/051855 WO2022133592A1 (en) 2020-12-21 2021-12-21 Stabilized tcr constructs and methods of use

Publications (1)

Publication Number Publication Date
CN116648256A true CN116648256A (zh) 2023-08-25

Family

ID=82157307

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180086149.4A Pending CN116648256A (zh) 2020-12-21 2021-12-21 稳定化的tcr构建体及使用方法

Country Status (8)

Country Link
US (1) US20240409604A9 (https=)
EP (1) EP4263593A4 (https=)
JP (1) JP2023554119A (https=)
KR (1) KR20230123474A (https=)
CN (1) CN116648256A (https=)
AU (1) AU2021408160A1 (https=)
CA (1) CA3167637A1 (https=)
WO (1) WO2022133592A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118108833A (zh) * 2024-03-12 2024-05-31 缇纱(合肥)生物技术有限公司 引入外源二硫键的tcr恒定区及其产品和应用
WO2025087436A1 (zh) * 2023-10-27 2025-05-01 北京可瑞生物科技有限公司 基于t细胞受体的多特异性多肽分子及其组合物和用途
WO2025140554A1 (en) * 2023-12-29 2025-07-03 Shanghai Epimab Biotherapeutics Co., Ltd. Fusion proteins and uses thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202000025SA (en) 2017-07-14 2020-02-27 Immatics Biotechnologies Gmbh Improved dual specificity polypeptide molecule
EP4334361A1 (en) 2021-05-05 2024-03-13 Immatics Biotechnologies GmbH Antigen binding proteins specifically binding prame
WO2025214470A1 (zh) * 2024-04-12 2025-10-16 江苏恒瑞医药股份有限公司 包含t细胞受体恒定区的蛋白质及其医药用途
WO2025224084A1 (en) 2024-04-22 2025-10-30 Engimmune Therapeutics Ag Proteins comprising t cell receptor constant domains

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110139873A (zh) * 2016-10-03 2019-08-16 朱诺治疗学股份有限公司 Hpv特异性结合分子
CN117843810A (zh) * 2017-09-22 2024-04-09 上海药明生物技术有限公司 新型双特异性多肽复合物
AU2018337142B2 (en) * 2017-09-22 2025-07-03 Wuxi Biologics Ireland Limited. Novel bispecific CD3/CD19 polypeptide complexes
BR112020006643A2 (pt) * 2017-10-03 2020-09-24 Juno Therapeutics Inc moléculas de ligação específica ao hpv
KR20210020873A (ko) * 2018-04-05 2021-02-24 주노 쎄러퓨티크스 인코퍼레이티드 재조합 수용체를 발현하는 τ 세포, 관련 폴리뉴클레오티드 및 방법
AU2019249209A1 (en) * 2018-04-05 2020-10-15 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025087436A1 (zh) * 2023-10-27 2025-05-01 北京可瑞生物科技有限公司 基于t细胞受体的多特异性多肽分子及其组合物和用途
WO2025140554A1 (en) * 2023-12-29 2025-07-03 Shanghai Epimab Biotherapeutics Co., Ltd. Fusion proteins and uses thereof
CN118108833A (zh) * 2024-03-12 2024-05-31 缇纱(合肥)生物技术有限公司 引入外源二硫键的tcr恒定区及其产品和应用

Also Published As

Publication number Publication date
US20240052009A1 (en) 2024-02-15
KR20230123474A (ko) 2023-08-23
CA3167637A1 (en) 2022-06-30
JP2023554119A (ja) 2023-12-26
WO2022133592A1 (en) 2022-06-30
AU2021408160A1 (en) 2023-06-29
EP4263593A1 (en) 2023-10-25
US20240409604A9 (en) 2024-12-12
EP4263593A4 (en) 2025-05-07

Similar Documents

Publication Publication Date Title
JP7410143B2 (ja) 二重特異性抗体及びその用途
CN116648256A (zh) 稳定化的tcr构建体及使用方法
US12559555B2 (en) Anti-LILRB4 antibodies and derivative products
JP7847584B2 (ja) 免疫細胞機能をモジュレートするためのｃｄ８抗原結合分子を有する融合物
EP2409991B1 (en) Antibody constant region variant
US20130177555A1 (en) Monomeric Polypeptides Comprising Variant FC Regions And Methods Of Use
CA3130508A1 (en) Antibody molecules that bind to nkp30 and uses thereof
TW202118788A (zh) 包含血管舒緩素相關肽酶2抗原結合域之蛋白質及其用途
KR20190060821A (ko) IL-15/IL-15Rα FC-융합 단백질 및 PD-1 항체 단편을 포함하는 이중특이성 이종이량체 융합 단백질
CA3131016A1 (en) Multifunctional molecules that bind to calreticulin and uses thereof
TW201100542A (en) Antibody constant region variant
US20220010015A1 (en) Antibodies binding to cd3
EP4303231A1 (en) Bispecific antibody
CN115768482A (zh) 结合siglec-3/cd33的材料和方法
TW202346337A (zh) Ilt3及cd3結合劑以及其使用方法
JP2025542327A (ja) 新規抗ｇｐｒｃ５ｄ抗体
US20250243275A1 (en) Multi-domain binding molecules
JP7837331B2 (ja) Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物
CA3149939A1 (en) Proteins comprising t-cell receptor constant domains
CN118562015A (zh) 一种针对cd20/cd3的双异性抗体及其制备方法和应用
HK40099262A (zh) 稳定化的tcr构建体及使用方法
KR20260042160A (ko) 이중특이적 폴리펩티드 분자
KR20250067799A (ko) 항-flag 항체
CN116997362A (zh) 含调节免疫细胞功能的cd8抗原结合分子的融合物
TW202600597A (zh) 靶向ｄｌｌ３之三特異性抗體構築體及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB02 Change of applicant information

Address after: British Columbia

Applicant after: Enzymatic British Columbia Ltd.

Address before: British Columbia

Applicant before: Yeast Biopharmaceutical Co.,Ltd.

CB02 Change of applicant information
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40099262

Country of ref document: HK